Flocculated suspension of megestrol acetate
AssigneePharmaceutical Resources, Inc.
InventorsN. Ragunathan, James C. Chao, Robert A. Femia, Malcolm S.F. Ross
Life of this patent
Estimating the term…
Abstract
A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.
Claims22
An oral pharmaceutical composition in the form of a stable flocculated suspension in water comprising:
- (a) megestrol acetate;
- (b) at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol;
- and
- (c) a surfactant,
- wherein polysorbate and polyethylene glycol are not simultaneously present in said composition.
An oral pharmaceutical composition in the form of a stable flocculated suspension in water comprising on a percent weight/volume basis about 4% megestrol acetate, about 0.0005-0.030% docusate sodium, up to about 20% glycerol, up to about 20% sorbitol, about 0.1-0.35% xanthan gum, about 0.1-0.3% sodium benzoate, about 0.3% citric acid, about 0.06% sodium citrate, about 5% sucrose, about 0.08% flavor, and the remainder water.
An oral pharmaceutical composition in the form of a stable flocculated suspension in water comprising on a percent weight/volume basis about 4% megestrol acetate, about 0.0005-0.030% polyoxyethylene 40 stearate, up to about 20% glycerol, up to about 20% sorbitol, about 0.1-0.35% xanthan gum, about 0.1-0.3% sodium benzoate, about 0.3% citric acid, about 0.06% sodium citrate, about 5% sucrose, about 0.08% flavor, and the remainder water.
Dependencies are inferred from the claim text.